Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/10/2017
SIETES contiene 92076 citas

 
 
 1 a 20 de 5680 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value . Ann Intern Med 2017;167:268-74. [Ref.ID 102038]
2. Cita con resumen
de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]
3. Cita con resumen
Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH. Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients – Detection frequencies and consistency with drug records. Br J Clin Pharmacol 2017;83:1397-404. [Ref.ID 101985]
4. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
5. Cita con resumen
Billionnet C, Alla F, Bérigaud É, Pariente A, Maura G. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases . Pharmacoepidemiol Drug Saf 2017;26:535-43. [Ref.ID 101959]
6. Cita con resumen
Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf 2017;26:481-97. [Ref.ID 101957]
7. Cita con resumen
Pacurariu AC, Coloma PM, Gross-Martirosyan L, Sturkenboom MC, Straus SM. Decision making in drug safety — A literature review of criteria used to prioritize newly detected safety issues. Pharmacoepidemiol Drug Saf 2017;26:327-34. [Ref.ID 101955]
9. Cita con resumen
Nevitt SJ, Marson AG, Davie B, Reynolds S, Williams L, Smith CT. Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review. BMJ 2017;357:j1390. [Ref.ID 101632]
12. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
13.Enlace a cita original
Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med 2017;376:381-91. [Ref.ID 101395]
14. Cita con resumen
Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]
15.Enlace a cita original
Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA 2016;316:1818-9. [Ref.ID 100935]
17.Enlace a cita original Cita con resumen
Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen T-T, Laine C. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ 2016;354:i5078. [Ref.ID 100797]
18.Enlace a cita original Cita con resumen
Mahtani KR, Heneghan C. Novel oral anticoagulants for atrial fibrillation. BMJ 2016;354:i5187. [Ref.ID 100782]
19. Cita con resumen
Anónimo. Understanding observational studies. Drug Ther Bull 2016;54:105-8. [Ref.ID 100726]
20. Cita con resumen
Hutton B, Catalá-López F, Moher D. La extensión de la declaración PRISMA para revisiones sistemáticas que incorporan metaanálisis en red: PRISMA-NMA. Med Clin (Barc) 2016;147:262-6. [Ref.ID 100724]
Seleccionar todas
 
 1 a 20 de 5680 siguiente >>